PMID- 37451014
OWN - NLM
STAT- MEDLINE
DCOM- 20230825
LR  - 20230825
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 122
DP  - 2023 Sep
TI  - Time-dependent changes in the glycolytic pathway in activated T cells are 
      independent of tumor burden or anti-cancer chemotherapy.
PG  - 110622
LID - S1567-5769(23)00947-5 [pii]
LID - 10.1016/j.intimp.2023.110622 [doi]
AB  - Although activated adoptive T cells therapy (ATC) is an effective approach for 
      cancer treatment, it is not clear how modulation of T cell activation impacts 
      their biochemical signature which significantly impacts the cell function. This 
      study is aimed to investigate the impact of polyclonal activation on the 
      metabolic signature of T cells from tumor-bearing mice under different settings 
      of treatment with chemotherapy. Thirty female Swiss albino mice were divided into 
      5 groups (n = 6/each), Gp1(PBS), groups Gp2 were inoculated intraperitoneal (i.p) 
      with 1 x 106 cells/mouse Ehrlich ascites carcinoma (EAC), Gp3-Gp5 were treated 
      with cisplatin (20 mg/mice) which were represented as EAC/CIS/1wk Or EAC/CIS/2wk 
      3 times every other day. Splenocytes were cultured in or presence of 
      concanavalin-A (Con-A) and IL-2 for 24 h or 72 h, then cells were harvested, and 
      processed to determine the enzyme activities of hexokinase (HK), 
      phosphofructokinase (PFK), lactate dehydrogenase (LDH) and glucose 6 phosphate 
      dehydrogenase(G6PD) enzymes. The results showed that before culture, T cells 
      harvested from EAC/PBS/1wk of mice or inoculated with EAC/CIS/1wk showed higher 
      activity in HK, PFK, LDH, and G6PH as compared to naive T cells. After 24, and 
      72 h of culture and activation, the enzyme activities in T cells harvested from 
      EAC/CIS/2wk mice or EAC/CIS/3wk mice decreased compared with their control. The 
      late stage of the tumor without chemotherapy gives a low glycolic rate. In late 
      activation, naive and early stages of the tumor with chemotherapy can give high 
      glycolic metabolism. These results show great significance as an application of 
      adoptive T-cell therapy.
CI  - Copyright (c) 2023. Published by Elsevier B.V.
FAU - Khalil, Sohaila M
AU  - Khalil SM
AD  - Immunology and Biotechnology Division, Zoology Department, Faculty of Science, 
      Tanta University, Tanta, Egypt; Center of Excellence in Cancer Research, New 
      Tanta University Teaching Hospital, Tanta University, Egypt. Electronic address: 
      Sohaila_galal@science.tanta.edu.eg.
FAU - Eltaramsy, Asmaa
AU  - Eltaramsy A
AD  - Physiology Division, Zoology Department, Faculty of Science, Tanta University, 
      Tanta, Egypt.
FAU - Hegazi, Mona M
AU  - Hegazi MM
AD  - Physiology Division, Zoology Department, Faculty of Science, Tanta University, 
      Tanta, Egypt.
FAU - Mohamed, Tarek M
AU  - Mohamed TM
AD  - Biochemistry Division, Department of Chemistry, Faculty of Science, Tanta 
      University, Egypt.
FAU - Alwasel, Saleh
AU  - Alwasel S
AD  - Zoology Department, College of Science, King Saud University, Riyadh, Saudi 
      Arabia.
FAU - Salem, Mohamed L
AU  - Salem ML
AD  - Immunology and Biotechnology Division, Zoology Department, Faculty of Science, 
      Tanta University, Tanta, Egypt; Center of Excellence in Cancer Research, New 
      Tanta University Teaching Hospital, Tanta University, Egypt. Electronic address: 
      mohamed.labib@science.tanta.edu.eg.
LA  - eng
PT  - Journal Article
DEP - 20230712
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Female
MH  - Animals
MH  - Mice
MH  - Tumor Burden
MH  - *Cisplatin/pharmacology/therapeutic use
MH  - Ascites
MH  - *Carcinoma, Ehrlich Tumor/drug therapy
OTO - NOTNLM
OT  - Activation
OT  - Cisplatin
OT  - Ehrlich ascites carcinoma
OT  - In vitro
OT  - Metabolism
OT  - T cells
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/07/15 10:42
MHDA- 2023/08/25 06:42
CRDT- 2023/07/14 18:02
PHST- 2023/04/13 00:00 [received]
PHST- 2023/06/27 00:00 [revised]
PHST- 2023/07/05 00:00 [accepted]
PHST- 2023/08/25 06:42 [medline]
PHST- 2023/07/15 10:42 [pubmed]
PHST- 2023/07/14 18:02 [entrez]
AID - S1567-5769(23)00947-5 [pii]
AID - 10.1016/j.intimp.2023.110622 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2023 Sep;122:110622. doi: 10.1016/j.intimp.2023.110622. Epub 
      2023 Jul 12.